Biofrontera submits FDA application to expand Ameluz red light PDT to full-body actinic keratoses
BFRI•Biofrontera submitted a supplemental new drug application to the FDA to expand Ameluz red light photodynamic therapy to actinic keratoses on the full body.
1. FDA application
Biofrontera submitted a supplemental new drug application to the FDA seeking to expand Ameluz red light photodynamic therapy to actinic keratoses on the full body.
